Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoDynSTU:296 -1.18%31 Cash Ratio is 0.31 as of Feb. 2026, which is 210% above its 10-year median of 0.10. GuruFocus rates STU:296 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,355 Biotechnology companies, CytoDyn ranks worse than 87.53% on this metric.
CytoDyn has a Cash Ratio of 0.31. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for CytoDyn's Cash Ratio or its related term are showing as below:
STU:296'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.1 Max: 2.69
Current: 0.31
During the past 13 years, CytoDyn's highest Cash Ratio was 2.69. The lowest was 0.01. And the median was 0.10.
STU:296's Cash Ratio is ranked worse than 87.53% of 1355
companies
in the Biotechnology industry
Industry Median: 2.96
vs STU:296: 0.31
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
CytoDyn Cash Ratio Related Terms
CytoDyn Cash Ratio Historical Data
* Premium members only.
The historical data trend for CytoDyn's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:296 vs BCYC, ALXO, SABS: Cash Ratio Comparison
For the Biotechnology subindustry, CytoDyn's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoDyn Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoDyn's Cash Ratio distribution charts can be found below:
* The bar in red indicates where CytoDyn's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoDyn (STU:296) has a Cash Ratio of 0.31 as of Feb. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on CytoDyn and its competitors. This is 210% above median its historical median of 0.10. Over the past decade, CytoDyn's Cash Ratio has ranged from 0.01 to 2.69. According to the industry distribution chart, CytoDyn ranks #1186 out of 1355 companies in the Biotechnology industry, placing it in the top 87.5%.
Is CytoDyn's Cash Ratio too high?
CytoDyn's current Cash Ratio of 0.31 is 210% above median its 10-year median of 0.10. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 2.69. The Biotechnology industry median Cash Ratio is 2.96. CytoDyn's value of 0.31 is 89.5% below this industry median. Based on the distribution chart, CytoDyn ranks #1186 out of 1355 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CytoDyn has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Cash Ratio compare to BCYC and ALXO?
According to the Biotechnology industry distribution chart, CytoDyn ranks #1186 out of 1355 companies for Cash Ratio. This places CytoDyn in the lower half of its industry. The industry median Cash Ratio is 2.96. CytoDyn's value of 0.31 is 89.5% below this benchmark. Historically, CytoDyn's own Cash Ratio has ranged from 0.01 to 2.69 over the past decade. While the company's 10-year median is 0.10 vs. the industry median of 2.96, CytoDyn has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytoDyn's current Cash Ratio of 0.31 is 89.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on CytoDyn and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoDyn's current Cash Ratio is 0.31, which is 210% above median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Cash Ratio of 0.31. The current Cash Ratio is 0.31, which is 210% above median its 10-year median of 0.10 and 89.5% below the Biotechnology industry median of 2.96. CytoDyn's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For CytoDyn (STU:296), the current Cash Ratio is 0.31 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
31GF Score
Get the complete analysis for STU:296
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:296 has been successfully added to your 
